PLoS ONE has just published a study which defines a gene locus on chromosome 1 that predicts prognosis of brain tumor patients and may even set the basis for the development of more efficient drugs to combat brain cancer.
Obese and very obese patients have a lower risk of dying after they have been treated for heart attacks than do normal weight patients, according to research published in the European Heart Journal.
The general public are worryingly ignorant about the symptoms and risk factors that contribute to serious medical conditions such as stroke and HIV/AIDS, according to a study published in the online open access journal BMC Medicine.
Adults who have recovered from the potentially deadly H5N1 strain of avian influenza may hold the key to future treatments for the virus, according to an international team of researchers.
Securing its place as an indispensable defence against the development and spread of drug-resistant tuberculosis (TB), the Stop TB Partnership announced today that its drug supply arm, the Global Drug Facility, has provided anti-TB drug treatments for 10 million people to 78 countries in the past six years.
Roche today announced the agreement of two new technology transfers with local manufacturing companies in Africa — Addis Pharmaceutical Factory in Ethiopia and Varichem Pharmaceuticals in Zimbabwe.
Using antibodies derived from immune cells from recent human survivors of H5N1 avian influenza to successfully treat H5N1-infected mice as well as protect them from an otherwise lethal dose of the virus, revealed by researchers.
An international team of scientists, including researchers from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, report using antibodies derived from immune cells from recent human survivors of H5N1 avian influenza to successfully treat H5N1-infected mice as well as protect them from an otherwise lethal dose of the virus.
Some cancers seem to be linked to extremely low frequency electromagnetic fields, suggests research published ahead of print in Occupational and Environmental Medicine.
GlaxoSmithKline announced an important milestone for advanced breast cancer patients across Europe with approval of the first oral ErbB1 and ErbB2 dual inhibitor, Tyverb? (lapatinib).